Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease–mineral and bone disorder (CKD-MBD) represents a systemic complication of chronic kidney disease, contributing significantly to increased morbidity and mortality. Several experimental models of CKD-MBD have been widely used to induce CKD-MBD-like phenotypes. However, in patients with CKD, renal dysfunction is frequently driven by glomerular pathology, and existing models fail to recapitulate the complex pathophysiology of CKD-MBD. Thus, establishing a pathophysiologically relevant animal model is imperative for elucidating the mechanisms underlying CKD-MBD and developing effective therapeutic interventions. In this study, we aimed to establish a mouse model of CKD-MBD that recapitulates human pathophysiology, using Nephrin-hCD25 (NEP25) transgenic (Tg) mice.
At 8 weeks of age, male NEP25 Tg mice were injected with LMB2 at a dose of 0.9 ng/g body weight. Throughout the study, mice had free access to standard mouse chow or modified AIN93G purified diet. All experiments were conducted with n=3–5, and each experiment was repeated at least three times.
Under standard diet conditions, LMB2-treated mice developed proteinuria and glomerulosclerosis. While plasma phosphate (Pi) levels remained unchanged compared to non-treated controls, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23) levels were significantly elevated. In contrast, under the AIN93G diet, LMB2-treated mice exhibited significant increases in plasma Pi, PTH, and FGF23 levels. Furthermore, under the AIN93G diet, micro-computed tomography analysis revealed marked reductions in bone mineral density and deterioration of trabecular architecture in both cortical and cancellous bone compartments in LMB2-treated mice. In addition, in the vascular smooth muscle of LMB2-treated mice under the AIN93G diet, there was a significant increase in the mRNA expression of RUNX2 and SPP1.
These findings indicate that NEP25 transgenic mice represent a valuable and reliable model for analyzing the pathophysiology of CKD-MBD.
